Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028609 | 0.86 | FFAR4 (0.56) | FFAR4FFAR1 | |
| SCHEMBL15265030 | 0.85 | FFAR4 (0.49) | FFAR4FFAR1 | |
| SCHEMBL17028569 | 0.83 | FFAR4 (0.48) | FFAR4FFAR1 | |
| SCHEMBL17028598 | 0.82 | FFAR4 (0.54) | FFAR4FFAR1 | |
| SCHEMBL15265930 | 0.81 | FFAR4 (0.53) | FFAR4MAOBFFAR1 | |
| SCHEMBL17028648 | 0.81 | FFAR4 (0.73) | FFAR4FFAR1 | |
| SCHEMBL17028696 | 0.80 | FFAR4 (0.61) | FFAR4FFAR1 | |
| SCHEMBL17028636 | 0.80 | FFAR4 (0.69) | FFAR4FFAR1 | |
| SCHEMBL3933040 | 0.79 | FAAH (0.43) | CYSLTR2CYSLTR1POLB | |
| SCHEMBL17028546 | 0.78 | FFAR4 (0.54) | FFAR4CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | FFAR4 26/4885CYSLTR2 114/4885CYSLTR1 214/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | FFAR4 26/4885CYSLTR2 114/4885CYSLTR1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.